Acurx Pharmaceuticals (ACXP) Q2 FY26 earnings call

Acurx Pharmaceuticals reported on its Q2 FY26 results, highlighting positive FDA guidance for its ibezapolstat development program, including the potential for a single pivotal Phase III study for acute CDI and recurrence prevention. The company also secured significant funding to support its PATHFINDER trial and operations for over a year, while advancing its pipeline with new partnerships and preclinical data. However, funding for the larger ASPIRE Phase III trial remains a key focus.